research use only
Cat.No.S7378
| Related Targets | HDAC Caspase Proteasome Secretase MMP HCV Protease Cysteine Protease Tyrosinase DPP HIV Protease |
|---|---|
| Other Serine Protease Inhibitors | Leupeptin Hemisulfate PMSF Nafamostat mesilate (FUT-175) Sivelestat Gabexate Mesylate Alvelestat (AZD9668) Sivelestat sodium tetrahydrate UK-371804 HCl Ulinastatin Fulacimstat |
|
In vitro |
DMSO
: 100 mg/mL
(417.2 mM)
Water : 100 mg/mL Ethanol : 50 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 239.69 | Formula | C8H11ClFNO2S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 30827-99-7 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1=CC(=CC=C1CCN)S(=O)(=O)F.Cl | ||
| Features |
Broad spectrum, irreversible serine protease inhibitor.
|
|---|---|
| Targets/IC50/Ki |
serine protease
|
| In vitro |
AEBSF inhibits the constitutive production of Aβ by directly inhibiting β-secretase in five different human cell lines, both neural and nonneural. AEBSF, as a serine protease inhibitor, inhibits the lysis of leukemic cells by human macrophages without inhibiting macrophage secretion of TNF-α and IL-1β. AEBSF also disturbs the growth of blastocysts on endometrial cells and inhibit the adhesion of HeLa cells on HUVECs by altering the protein secretion pattern.
|
| In vivo |
AEBSF (76.8 mg/kg daily i.p.) results in prolongation of the survival of mice that have been given a lethal T. gondii infection. AEBSF also reduces airway response and underlying inflammation in cockroach allergen-induced murine model.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.